Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XXB750 in Healthy Participants
NCT06558097Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xxb750 in hypertension (HTN) (11 arms), sponsored by Novartis. Primary endpoint: Number of participants with Adverse Events up to 121 days. Started Jul 2020; status: completed.
02
Drugs
xxb750
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06558097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558097.